How much cash does Aardvark Therapeutics, Inc. Common Stock generate?

Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.

Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Aardvark Therapeutics, Inc. Common Stock AARD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$69.87M-152%	-$57.59M-180%	-$48.77M—	-$36.64M—	-$27.72M—
Depreciation and amortization	$42K+121%	$36K+125%	$34K—	$32K—	$19K—
Stock-based compensation	$5.72M+845%	$3.95M+799%	$2.54M—	$1.19M—	$605K—
Provision for credit losses	——	$0-100%	$0—	$0—	$14K—
Change in accounts payable	——	——	——	$3.83M—	$1.89M—
Change in accrued liabilities	$3.75M+61.9%	$6.42M+362%	$4.24M—	$3.51M—	$2.31M—
Change in other assets	$2.02M—	$6.04M—	$5.96M—	——	——
Net gains (losses) on investments	-$3K+97.5%	-$5K+97.7%	-$32K—	-$159K—	-$122K—
Change in operating lease liabilities	-$390K-74.1%	-$338K-70.7%	-$323K—	-$278K—	-$224K—
Net cash from operating activities	-$61.65M-126%	-$54.17M-200%	-$45.09M—	-$32.91M—	-$27.29M—
Capital expenditures	——	$95K-12.8%	$101K—	$102K—	$104K—
Purchases of investments	——	——	——	——	$136.54M—
Proceeds from maturities/sales of investments	$102.25M+750%	$80.03M—	$50.78M—	$21.53M—	$12.03M—
Net cash from investing activities	——	——	——	——	-$124.62M—
Proceeds from issuance of common stock	——	——	$118K—	$116K—	$110K—
Payment of debt issuance costs	——	$0-100%	$298.25K—	$596.5K—	$894.75K—
Net cash from financing activities	$449K-99.7%	$89.32M+7.6%	$89.05M—	$88.94M—	$171.88M—
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$1.34M+659%	$1.31M+1,260%	$1.17M—	$797K—	$177K—
Operating lease liabilities	-$390K-74.1%	-$338K-70.7%	-$323K—	-$278K—	-$224K—
Increase (Decrease) in Prepaid Expense and Other Assets	$2.02M—	$6.04M—	$5.96M—	——	——
Lessee Operating Non Cash Lease Expense	$359K+13.2%	$380K+61.7%	$402K—	$398K—	$317K—
Payments to Acquire Short-Term Investments	——	——	——	——	$136.54M—
Proceeds from maturities of short-term investments	$102.25M+750%	$80.03M—	$50.78M—	$21.53M—	$12.03M—
Payments Of Stock Issuance Costs	——	——	——	$2.39M—	$2.31M—
Net proceeds from sales of subsidiary shares	——	——	——	——	$91.08M—
Increase Decrease In Operating Lease Liability	-$390K-74.1%	-$338K-70.7%	-$323K—	-$278K—	-$224K—
Leased assets obtained in exchange for operating lease liabilities	——	$0-100%	$203.75K—	$407.5K—	$611.25K—
Unrealized Gain (Loss) on Investments	-$3K+97.5%	-$5K+97.7%	-$32K—	-$159K—	-$122K—
Conversion Of Convertible Preferred Stock Into Common Stock Upon Initial Public Offering	——	——	——	——	$126.76M—
Deferred Financing Costs Included In Accounts Payable And Accrued Expenses	——	$0-100%	$284K—	$568K—	$852K—
Early Exercise Options And Unvested Stock Liability	——	$26K+225%	$21.5K—	$17K—	$12.5K—
Free cash flow	——	-$54.27M-198%	-$45.19M—	-$33.02M—	-$27.39M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Aardvark Therapeutics, Inc. Common Stock generate?: Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.